Divalproex Sodium
Product Images NDC 50090-2795

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 50090-2795). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Divalproex Fig1)

A bar chart comparing the percentage outcomes between placebo (PBO) and divalproex sodium delayed-release tablets (DVPX) in two studies. Study 1 (YMRS) shows 26% for placebo and 60% for DVPX. Study 2 (MRS) shows 29% for placebo and 58% for DVPX. Significance is noted with p < 0.05.*

FDA Label Image

Figure 2 (Divalproex Fig2)

A line graph titled 'Figure 2' showing percent reduction in CPS rate on the y-axis and percent of patients on the x-axis. It compares the effects of Divalproex Sodium Delayed-Release Tablets versus placebo, illustrating patient response distribution with two distinct lines.*

FDA Label Image

Figure 3 (Divalproex Fig3)

A chart titled 'Figure 3' showing the percentage reduction in CRS rate on the vertical axis and percentage of patients on the horizontal axis. It compares high dose (solid line) and low dose (dashed line) treatments, with an indicated scale from worsening to improvement on the right side.*

FDA Label Image

Figure 4 (Divalproex Fig4)

A bar chart titled 'Figure 4 Mean 4-week Migraine Rates' comparing migraine rates between placebo and Divalproex Sodium delayed-release tablets in two separate studies. The y-axis shows migraine rates from 0 to 6. In both studies, migraine rates are lower in the Divalproex Sodium groups compared to placebo. Footnotes detail dosages used in the studies.*

FDA Label Image

Chemical Structure (Divalproex Str)

Chemical structure of the active ingredient in Divalproex Sodium, illustrating its molecular arrangement including carbon chains, hydroxyl groups, carboxylate groups, and a sodium ion.*

FDA Label Image

Label Image (Lbl500902795)

Packaging label for Divalproex Sodium 500 mg delayed release tablets by A-S Medication Solutions. The label states this is a 33-unit dose package of 55 release tablets. It includes storage instructions to keep at 68 to 77 degrees Fahrenheit and notes the product contains Divalproex Sodium USP equivalent to valproic acid 500 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.